Klinefelter Syndrome - the Effect of Testosterone Treatment in Puberty. a Randomized, Double-blind Placebo-controlled Intervention Study: 'The TiPY Study'
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Changes in body fat mass
研究概览
简要总结
The goal of this randomized clinical trial is to study the effect of testosterone replacement therapy during puberty in boys with Klinefelter syndrome (KS, 47,XXY).
The main questions to answer are how treatment with testosterone will affect body fat mass, lipid and glucose metabolism, growth and body proportions, bone mineralization as well as effects on neurocognitive development and emotional and social difficulties.
Participants will be randomized to two years treatment with testosterone or placebo.
详细描述
Klinefelter syndrome (KS, 47,XXY) is the most frequent sex chromosome disorder with a prevalence of 1:660 boys. Patients with KS are hypogonadal due to a progressive testicular destruction starting already in childhood. Consequently, the adult male with KS is characterized by small testes, signs of incomplete virilization (e.g. lack of voice deepening, sparse face and body hair, gynecomastia, low muscle mass, reduced penile length), hypergonadotropic hypogonadism, infertility and increased risk of metabolic syndrome, diabetes, cardiovascular disease, osteoporosis and psychosocial and neurodevelopmental challenges. Adults with KS have a poor health and a prevention of the major co-morbidities associated with KS and thereby an improvement in the general health would have an enormous impact on the life of a large cohort of males worldwide.
Sufficient testosterone is not only important in the adult but also during puberty and adolescence for a normal virilization and to improve body composition and body proportions, as well as to maximize peak bone mass acquisition. It has therefore been internationally accepted and makes biological sense to consider testosterone replacement therapy (TRT) during puberty in KS. However, there are no evidence based recommendations, and during recent years TRT in puberty has been questioned and is no longer recommended in some countries. There is a need on an international level for evaluating the effect of this treatment. We therefore aim at evaluating the effect of 2 years TRT during early puberty in boys with KS aged 10 to 14 years in this national, multi-center, randomized, double-blind, placebo-controlled intervention study. The primary endpoint is to evaluate the effect on body fat mass. The secondary endpoints are to evaluate effects on lipid and glucose metabolism, growth and body proportions, bone mineralization as well as effects on neurocognitive development and emotional and social difficulties.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 10 Years 至 14 Years(Child)
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •47,XXY Klinefelter syndrome
- •Age 10-14 years at inclusion
- •Luteinizing Hormone > +2 standard deviations (SD) by ultrasensitive luteinizing hormone assay
- •Free Testosterone<+2 standard deviations
- •Signed consent from parents
排除标准
- •Previous or ongoing T treatment except for TRT because of micropenis
- •Contraindications to testosterone treatment known hypersensitivity to testosterone or to any other constituent of the gel known or suspected prostatic cancer or breast carcinoma
- •Participation in any other clinical trial
研究组 & 干预措施
Testosterone
Testosterone gel applied to the skin
干预措施: Testosterone gel (Drug)
Placebo
Placebo gel applied to the skin
干预措施: Placebo (Other)
结局指标
主要结局
Changes in body fat mass
时间窗: Baseline and 1 and two years
Evaluation of body fat percentage by whole body dual energy x-ray absorptiometry (DEXA) scan
次要结局
- Pubertal development and virilization(Every three months for two years)
- Pubertal development and viriliztion(Every three months for two years)
- Pubertal development(At base line, and at 1 and 2 years)
- Anthropometry(At base line, and at 1 and 2 years)
- Bone health(At base line, and at 1 and 2 years)
- Measurement of bone turnover markers(At base line, and at 1 and 2 years)
- Changes in growth(Base line and at 1 and 2 years)
- Measurement of serum concentrations of growth factors(At base line, and at 1 and 2 years)
- Muscle strength(Every three months for two years)
- Changes i QTc(Base line and at 1 and 2 years)
- Changes in markers of lipids(Base line and at 1 and 2 years)
- Changes in markers of metabolism(Base line and at 1 and 2 years)
- Changes in markers of inflammation(Base line and at 1 and 2 years)
- Neuropsychological evaluation(Baseline and after two years)
- Cryopreservation of spermatozoa(After 2 years)
- Epigenetic(At base line, and at 1 and 2 years)
- Genetic effects(At base line, and at 1 and 2 years)
- Small non-coding RNA(At base line, and at 1 and 2 years)
研究者
Lise Aksglæde
Principal investigator
Rigshospitalet, Denmark
